New drug targets genetic driver in advanced cancers
NCT ID NCT07359820
Summary
This study is testing whether an experimental drug called lirafugratinib can help control advanced solid tumors that have a specific genetic change called FGFR2 fusion or rearrangement. The trial is for adults whose cancer has spread or cannot be surgically removed and who have already tried at least one other treatment. Participants will take the oral medication regularly while doctors monitor how their tumors respond and track any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FGFR2 GENE FUSION/REARRANGEMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Leon Berard
Lyon, 69373, France
-
Gustave Roussy Cancer Campus
Paris, 94805, France
-
Hospital Universitario Fundación Jiménez Díaz- START MADRID
Madrid, 28040, Spain
-
Hospital Universitario HM Sanchinarro-START MADRID-CIOCC
Madrid, 28050, Spain
-
Institut Bergonie
Bordeaux, 33076, France
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10022, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
START Barcelona-Hospital HM Nou Delfos
Barcelona, 08023, Spain
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Sarah Cannon Research Institute UK
London, W1G 6AD, United Kingdom
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.